CBAY — CymaBay Therapeutics Share News
0.000.00%
Last trade - 00:00- $3.73bn
- $3.44bn
- $31.07m
Brief: Seladelpar Granted Revised Breakthrough Therapy Designation For The Treatment Of Primary Biliary Cholangitis
Brief: Cymabay Initiates Affirm, A Phase 3B/4 Study Evaluating The Effect Of Seladelpar On Clinical Outcomes In Patients With Cirrhosis Due To Primary Biliary Cholangitis
Brief: Cymabay Announces Closing Of Upsized $258.7 Mln Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Cymabay Announces Pricing Of Upsized $225 Million Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Cymabay Announces Proposed $150 Million Public Offering Of Common Stock And Pre-Funded Warrants
U.S. RESEARCH ROUNDUP- Autozone, Sherwin-Williams, Walmart
U.S. STOCKS ON THE MOVE-Kodiak Sciences, Intensity Therapeutics, Inovio Pharma
CymaBay Therapeutics rises as liver disease drug succeeds in late-stage study
Brief: Cymabay's Seladelpar Achieves High Statistical Significance In The Phase 3 Response Trial
U.S. RESEARCH ROUNDUP-Dollar Tree, Hexcel, Humacyte
U.S. RESEARCH ROUNDUP-Autodesk, Bill Holdings, Zoetis
U.S. RESEARCH ROUNDUP-Caci International, Cyberark Software, Ralph Lauren
CymaBay Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
CymaBay Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Biotech index tumbles as FTC moves to block Amgen/Horizon deal
U.S. RESEARCH ROUNDUP-Albemarle, Ellington Financial, Savara
CymaBay Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cymabay Appoints Harish Shantharam As CFO
CymaBay Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview